News
BOLT
6.32
+0.32%
0.02
Weekly Report: what happened at BOLT last week (1102-1106)?
Weekly Report · 2d ago
Bolt Biotherapeutics Consensus Price Target Increased by 1,400% to $76.50
NASDAQ · 11/02 23:12
Weekly Report: what happened at BOLT last week (1026-1030)?
Weekly Report · 11/02 09:25
Weekly Report: what happened at BOLT last week (1019-1023)?
Weekly Report · 10/26 09:25
Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMAB
NASDAQ · 10/23 19:00
Why Is Penny Stock Bolt Biotherapeutics (BOLT) Up 62% Today?
TipRanks · 10/23 18:19
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/23 17:05
Bolt Biotherapeutics Acquires Prana, Secures $120M To Advance PRA-216 Pipeline; Stock Up
NASDAQ · 10/23 16:44
Bolt Biotherapeutics Completes Prana Merger, Refocuses Pipeline
TipRanks · 10/23 15:28
Bolt Biotherapeutics, Inc. Acquires Prana Therapies, Inc. and Secures $120 million Private Placement
NASDAQ · 10/23 15:09
Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement
NASDAQ · 10/23 13:58
Bolt Biotherapeutics Inc trading resumes
TipRanks · 10/23 13:55
Bolt Biotherapeutics acquires Prana Therapies
TipRanks · 10/23 13:25
Bolt’s Acquisition Positions It To Advance Prana’s Inspire Multispecific Antibody Pipeline; Phase 2 PRA-216 Readouts Expected Starting Q2 2027
Benzinga · 10/23 13:22
Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028
Benzinga · 10/23 13:19
*Bolt Biotherapeutics Following Transaction, Prana Co-Founder and Former CEO Sheila Gujrathi Will Join Bolt's Executive Team and Bolt's Bd of Directors >BOLT
Dow Jones · 10/23 13:19
*Bolt Biotherapeutics: Acquisition Was Structured as a Sign-And-Close Reverse Merger >BOLT
Dow Jones · 10/23 13:19
Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing
Benzinga · 10/23 13:17
Press Release: Bolt Biotherapeutics Announces -2-
Dow Jones · 10/23 13:08
Bolt Biotherapeutics Inc trading halted, news pending
TipRanks · 10/23 12:40
More
Webull provides a variety of real-time BOLT stock news. You can receive the latest news about Bolt Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.